- Home
- SBH vs SNDX Comparison
SBH vs SNDX Comparison
Compare SBH & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBH
- SNDX
- Stock Information
- Founded
- SBH 1964
- SNDX 2005
- Country
- SBH United States
- SNDX United States
- Employees
- SBH N/A
- SNDX N/A
- Industry
- SBH Other Specialty Stores
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- SBH Consumer Discretionary
- SNDX Health Care
- Exchange
- SBH Nasdaq
- SNDX Nasdaq
- Market Cap
- SBH 937.3M
- SNDX 1.1B
- IPO Year
- SBH 2006
- SNDX 2016
- Fundamental
- Price
- SBH $10.28
- SNDX $9.00
- Analyst Decision
- SBH Buy
- SNDX Strong Buy
- Analyst Count
- SBH 6
- SNDX 10
- Target Price
- SBH $12.70
- SNDX $35.80
- AVG Volume (30 Days)
- SBH 1.7M
- SNDX 1.8M
- Earning Date
- SBH 08-07-2025
- SNDX 07-31-2025
- Dividend Yield
- SBH N/A
- SNDX N/A
- EPS Growth
- SBH 18.05
- SNDX N/A
- EPS
- SBH 1.76
- SNDX N/A
- Revenue
- SBH $3,698,409,000.00
- SNDX $43,722,000.00
- Revenue This Year
- SBH N/A
- SNDX $426.77
- Revenue Next Year
- SBH $1.40
- SNDX $98.31
- P/E Ratio
- SBH $5.84
- SNDX N/A
- Revenue Growth
- SBH 0.17
- SNDX N/A
- 52 Week Low
- SBH $7.54
- SNDX $8.58
- 52 Week High
- SBH $14.79
- SNDX $25.07
- Technical
- Relative Strength Index (RSI)
- SBH 71.12
- SNDX 38.70
- Support Level
- SBH $8.66
- SNDX $8.77
- Resistance Level
- SBH $9.08
- SNDX $9.50
- Average True Range (ATR)
- SBH 0.32
- SNDX 0.53
- MACD
- SBH 0.16
- SNDX -0.04
- Stochastic Oscillator
- SBH 98.92
- SNDX 14.13
About SBH Sally Beauty Holdings Inc. (Name to be changed from Sally Holdings Inc.)
Sally Beauty Holdings Inc is a professional beauty-products retailer based in the United States. Sally Beauty operates throughout the United States, Puerto Rico, the United Kingdom, Belgium, Canada, Chile, Mexico, Peru, France, Ireland, Spain, Germany, and the Netherlands. The company operates through two business segments: Sally Beauty Supply and Beauty Systems Group. Product offerings include hair color and care, hair dryers and hair-styling appliances, nail care, skin care, and others.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.